Table 1 |
||||
|
Patient demographics at baseline |
||||
| β2-agonists + Placebo (N = 7) |
β2-agonists + Zafirlukast (N = 14) |
ICS-treated + Placebo (N = 8) |
ICS-treated + Zafirlukast (N = 16) |
|
|
|
||||
| Sex, male/female |
3/4 |
8/6 |
2/6 |
9/7 |
| Age, years |
29 (21–55) |
42 (21–69) |
45 (30–65) |
37 (19–65) |
| Ex-smoker |
2 |
4 |
5 |
6 |
| FEV1, L |
2.7 (2.3–3.7) |
2.1 (1.4–4.2) |
2.8 (2.0–3.8) |
2.7 (1.4–4.1) |
| Baseline FEV1, % predicted |
80 (65–102) |
85 (69–107) |
76 (60–95) |
77 (56–98) |
| Inhaled corticosteroid, μg/day |
NA |
NA |
1600 (1000–2400) |
1600 (1000–2400) |
| PD20 methacholine, μg * |
0.008 (0.001–0.04) |
0.04 (0.005–1.3) |
0.03 (0.004–0.2) |
0.02 (0.001–0.6) |
|
|
||||
|
Data are given as median and (range) except * geometric mean and (range). NA not applicable |
||||
|
Reid et al. Journal of Negative Results in BioMedicine 2008 7:3 doi:10.1186/1477-5751-7-3 |
||||
